| 1 |
Schatz IJ, Bannister R, Freeman C G, et al. The difinition of orthostatic hypotension, pure autonomic failure, andmultiple system atrophy [J]. J Auton Nerv syst, 1996, 58: 123-124.
|
| 2 |
Rignole M, Moya A, De Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope [J]. Eur Heart J, 2018, 39(21): 1883-1948.
|
| 3 |
Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope, and the postural tachycardia syndrome [J]. Clin Auton Res. 2011, 21(2): 69-72.
|
| 4 |
Lahrmann H, CortelIi P, Hilz M, et al. EFNs guidelines on the diagnosis and management of orthostatic hypotension [J]. Eur J Neural, 2006, 13(9): 930-936.
|
| 5 |
Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension [J]. JNeurol, 2017, 264(8): 1567-1582.
|
| 6 |
Kulkarni S, Jenkin D, Dhar A, et al. Treating lows: management of orthostatic hypotension [J]. J Cardiovasc Pharmacol, 2024, 84(3): 303-315.
|
| 7 |
Ricci F, Fedorowski A, Radico F, et al. Cardiovascular morbidity and mortality related to orthostatic hypotension: a meta-analysis of prospective observational studies [J]. Eur Heart J, 2015, 36: 1609-1617.
|
| 8 |
董荣芳, 张铭, 郑丹枫, 等. 糖尿病周围神经病的病理学研究 [J]. 诊断病理学杂志, 2015, 22(3): 6.
|
| 9 |
Stedman M, Robinson A, Dunn G, et al. Diabetes foot complications and standardized mortality rate in type 2 diabetes [J]. Diabetes Obes Metab, 2023, 25: 3662-3670.
|
| 10 |
Spallone V, Ziegler D, Freeman R, et al. Toronto consensus panel on diabetic neuropathy. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management [J]. Diabetes Metab Res Rev, 2011, 27: 639-653.
|
| 11 |
Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy [J]. Circulation, 2007, 115: 387-397.
|
| 12 |
Davis TME, Tan E, Davis WA. Prevalence and prognostic significance of cardiac autonomic neuropathy in community-based people with type 2 diabetes: the Fremantle Diabetes Study Phase II [J]. Cardiovasc Diabetol, 2024, 23: 102-118.
|
| 13 |
Wieling W, Kaufmann H, Claydon VE, et al. Diagnosis and treatment of orthostatic hypotension [J].Lancet Neurol, 2022, 21: 735-746.
|
| 14 |
Kaufmann H, Norcliffe-Kaufmann L, Palma J-A. Baroreflex dysfunction [J]. N Engl J Med, 2020, 382: 163-178.
|
| 15 |
Chowdhury M, Nevitt S, Eleftheriadou A, et al. Cardiac autonomic neuropathy and risk of cardiovascular disease and mortality in type 1 and type 2 diabetes: a meta-analysis [J]. BMJ Open Diabetes Res Care, 2021, 9: e002480.
|
| 16 |
Chisholm P, Anpalahan M. Orthostatic hypotension: pathophysiology,assessment, treatment, and paradox of supine hypertension [J]. Intern Med J, 2017, 47(4): 370-379.
|
| 17 |
Fanciulli A, Jordan J, Biaggioni I, et al. Supine hypertension and end-organ damage in autonomic failure [J]. J Hypertens, 2021, 39(5): 881-889.
|
| 18 |
Espay AJ, LeWitt PA, Hauser RA, et al. Neumgenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets [J]. Lancet Neurol, 2016 15: 954-966.
|
| 19 |
张宝荣. 神经源性直立性低血压及相关仰卧位高血压的筛查、诊断和治疗专家共识解读 [J/CD]. 中华老年病研究电子杂志, 2017, 4(2): 32-34.
|
| 20 |
Arnold AC, Raj SR, Ablonczy Z, et al. 2023 ACC expert consensus on the evaluation and management of autonomic dysfunction [J]. J Am Coll Cardiol, 2023, 82(5): 1183-1202.
|
| 21 |
Jordan J, Fanciulli A, Tank J, et al. Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension [J]. J Hypertens, 2019, 37: 1541-1546.
|